The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail


150 milligram(s) Capsule, hard

Boehringer Ingelheim International GmbHEU/1/08/442/009-013

Main Information

Trade NamePradaxa
Active SubstancesDabigatran etexilate mesilate
Strength150 milligram(s)
Dosage FormCapsule, hard
Licence HolderBoehringer Ingelheim International GmbH
Licence NumberEU/1/08/442/009-013

Group Information

ATC CodeB01AE Direct thrombin inhibitors
B01AE07 dabigatran etexilate


Licence Issued
Legal statusProduct subject to prescription which may be renewed (B)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusUnknown


Summary of Product CharacteristicsSearch EMA website
Package LeafletSearch EMA website
Public Assessment ReportSearch EMA website

Educational Materials - Patient

« Back